Clinical Evidence Base

Publications & References

Peer-reviewed citations supporting Prapela SVS clinical evidence — including the pivotal RCT, supporting clinical trial, and peer-reviewed NOWS management literature.

Prapela SVS Pivotal Clinical Trial
Randomized Clinical Trial
Bloch-Salisbury E, Wilson JD, Rodriguez N, Bruch T, McKenna L, Derbin M, Glidden B, Ayturk D, Aurora S, Yanowitz T, Barton B, Vining M, Beers SR, & Bogen DL.
Efficacy of a Vibrating Crib Mattress to Reduce Pharmacologic Treatment in Opioid-Exposed Newborns: A Randomized Clinical Trial.
JAMA Pediatrics. 2023;177(7):665–674.
PMID: 37003713 https://doi.org/10.1001/jamapediatrics.2023.1077
⚕ Trial conducted under Finnegan assessment: SVS-treated infants met discharge threshold of ≤8 on Finnegan Neonatal Abstinence Scoring. SVS-on time (OR 0.88/hour, 95% CI 0.81–0.93) and caregiver hold time (OR 0.90/hour, 95% CI 0.86–0.94) each independently and significantly reduced likelihood of morphine treatment; post hoc analysis confirmed the two effects are additive. This is the pivotal trial underlying Prapela's FDA De Novo authorization.
Prapela SVS Supporting Clinical Trial
Foundational Research
Zuzarte I, Indic P, Barton B, Paydarfar D, Bednarek F, Bloch-Salisbury E.
Vibrotactile Stimulation: A Non-pharmacological Intervention for Opioid-Exposed Newborns.
PLoS ONE. 2017;12(4):e0175981.
PMID: 28437438 https://doi.org/10.1371/journal.pone.0175981
Foundational SVS Research
Multicenter RCT · NOWS
Singh R, Trinquart L, Koethe B, Cordova M, Rhein L, Bibi S, Fey J, Anderson A, Davis JM.
Efficacy of Stochastic Vibro-Tactile Stimulation for Newborns at Risk of Neonatal Opioid Withdrawal Syndrome.
Pediatric Research. 2025.
https://doi.org/10.1038/s41390-025-04162-2
Pilot Study · NOWS
Bloch-Salisbury E, Rodriguez N, Bruch T, McKenna L, Goldschmidt L.
Physiologic Dysregulation in Newborns with Prenatal Opioid Exposure: Cardiac, Respiratory and Movement Activity.
Neurotoxicology and Teratology. 2022;92:107105.
PMID: 35636615 https://doi.org/10.1016/j.ntt.2022.107105
Clinical Study · AOP
Smith VC, Kelty-Stephen D, Ahmad MQ, Mao W, Cakert K, Osborne J, Paydarfar D.
Stochastic Resonance Effects on Apnea, Bradycardia, and Oxygenation: A Randomized Controlled Trial.
Pediatrics. 2015;136(6):e1561–e1568.
PMID: 26527547 https://doi.org/10.1542/peds.2015-1334
Clinical Study · AOP
Bloch-Salisbury E, Indic P, Bednarek F, Paydarfar D.
Stabilizing Immature Breathing Patterns of Preterm Infants Using Stochastic Mechanosensory Stimulation.
Journal of Applied Physiology. 2009;107(4):1017–1027.
PMID: 19608934 https://doi.org/10.1152/japplphysiol.00058.2009
Foundational · First Clinical Observation
Paydarfar D, Buerkel DM.
Sporadic Apnea: Paradoxical Transformation to Eupnea by Perturbations that Inhibit Inspiration.
Medical Hypotheses. 1997;49(1):19–26.
PMID: 9247914 https://pubmed.ncbi.nlm.nih.gov/9247914/
Foundational · Mechanism
Paydarfar D, Buerkel DM.
Dysrhythmias of the Respiratory Oscillator.
Chaos. 1995;5(1):18–29.
PMID: 12780150 https://doi.org/10.1063/1.166067
Regulatory Authorization
Regulatory Authorization
U.S. Food and Drug Administration
De Novo Classification Request for Prapela SVS Hospital Bassinet Pad (Model P01). De Novo Summary DEN240031.
April 4, 2025.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN240031
⚕ FDA's benefit-risk determination found probable benefit in decreasing length of treatment and cumulative morphine dose in NOWS patients responsive to morphine treatment, and probable benefit in reducing caregiver burden from holding and rocking. Classified as a Therapeutic Vibrational Mattress Pad (21 CFR 880.5151, Product Code QVY, Class II).
Neonatal Opioid Withdrawal Syndrome: Supporting Clinical Literature
Clinical Trial — Lead Article
Devlin LA et al.; HELP for NOWS Consortium (NIH HEAL Initiative / NICHD Neonatal Research Network)
Symptom-Based Dosing for Neonatal Opioid Withdrawal: Outcomes from the OPTimize NOW Study.
JAMA. 2026.
https://doi.org/10.1001/jama.2026.5782
Multicenter cluster crossover RCT (n=626, 23 US sites). Symptom-based dosing reduced time to medical readiness for discharge by 2.3 days vs. scheduled opioid taper in ESC-managed infants (9.18 vs. 11.61 days; p=0.02). No significant difference in safety outcomes through 3 months. Effect size trends were similar in the Finnegan cohort. (Devlin et al., JAMA 2026)
Critical Reassessment
McGregor C, Graber R.
Reassessing the Eat, Sleep, Console Protocol: Evidence Gaps and Implications for Neonatal Opioid Withdrawal Syndrome Management.
Pediatric Research. 2026.
https://doi.org/10.1038/s41390-026-04948-y
⚠ This paper critically reassesses ESC's evidence base, arguing that reductions in LOS may reflect reduced pharmacological weaning rather than improved outcomes, and that long-term neurodevelopmental data remain lacking. SVS is compatible with both Finnegan and ESC-based care pathways regardless of this debate.
Quality Improvement Study
Ghadiali M, Kim ES, Freeman A, et al.
Implementing the Eat, Sleep, Console (ESC) Model in a Small Safety-Net Hospital: A Phased Quality Improvement Initiative.
Cureus. 2026;18(6):e110557.
https://doi.org/10.7759/cureus.110557
⚠ Single-center quality improvement initiative (ESC n=12 vs. FNASS n=24); findings are preliminary and the authors call for larger, multi-site studies to confirm generalizability.
A 2.5-year phased implementation at a Los Angeles safety-net hospital. ESC reduced length of stay and pharmacologic treatment — but the authors report that non-pharmacologic care increased nursing workload, requiring additional volunteers and support persons to sustain consoling demands and distribute the burden.
Cluster RCT
Young LW, Ounpraseuth ST, Merhar SL, Hu Z, Simon AE, Bremer AA, Lee JY, Das A, Crawford MM, Greenberg RG, Smith PB, Poindexter BB, Higgins RD, Walsh MC, et al.; ACT NOW Collaborative.
Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal.
N Engl J Med. 2023;388(25):2326–2337.
PMID: 37125831 https://doi.org/10.1056/NEJMoa2214470
Post Hoc Subgroup Analysis
Devlin LA, Hu Z, Merhar SL, Ounpraseuth ST, Simon AE, Lee JY, Das A, Crawford MM, Greenberg RG, Smith PB, et al.; NICHD Neonatal Research Network.
Influence of Eat, Sleep, and Console on Infants Pharmacologically Treated for Opioid Withdrawal: A Post Hoc Subgroup Analysis of the ESC-NOW Randomized Clinical Trial.
JAMA Pediatr. 2024;178(6):525–532.
PMID: 38619854 https://doi.org/10.1001/jamapediatrics.2024.0544
Review
Mascarenhas M, Wachman EM, Chandra I, Xue R, Sarathy L, Schiff DM.
Advances in the Care of Infants With Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome.
Pediatrics. 2024;153(2):e2023062871.
PMID: 38178779 https://doi.org/10.1542/peds.2023-062871
Meta-Analysis
Chu L, Liu X, Xu C.
Eat, Sleep, Console Model for Neonatal Opioid Withdrawal Syndrome: A Meta-Analysis.
Front Pediatr. 2024;12:1416383.
PMID: 39220152 https://doi.org/10.3389/fped.2024.1416383
QI Cohort Study
Halloum H, Daniels BJ, Beville D, Thrasher K, Martin GC, Ellsworth MA.
Implementation of a Nurse-Driven Eat-Sleep-Console (ESC) Treatment Pathway at a Community Hospital for Treatment of Neonatal Opioid Withdrawal Syndrome in an Effort to Improve Short-term Outcomes.
Adv Neonatal Care. 2024;24(3):212–218.
PMID: 38127593 https://doi.org/10.1097/ANC.0000000000001123
Comparative Evidence: Non-FDA-Authorized Devices
Retrospective Cohort Study
Robinson TW, Stikes R, Sorrell J, Gater A, Booth AT, Gardner A, Greenwell C, Businger S, Low R, Petrie R.
Treatment for Neonatal Abstinence Syndrome Using Nonpharmacological Interventions.
Am J Perinatol. 2024;41(16):2198–2205.
https://doi.org/10.1055/s-0044-1786744
⚠ Retrospective cohort study found a responsive rocking bassinet intervention was associated with worse outcomes vs. standard nonpharmacological care — longer LOS, doubled morphine exposure, worse sleep scores. Study was discontinued early following interim review.
FDA Regulatory Action
U.S. Food and Drug Administration
Warning Letter: Happiest Baby, Inc. MARCS-CMS 718306.
June 15, 2026.
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happiest-baby-inc-718306-06152026
⚠ FDA found the SNOO Smart Sleeper and SNOO Hospital Bundle adulterated and misbranded due to undisclosed device modifications, including marketing for hospital use never evaluated under the device's home-use-only authorization (DEN210039). Corroborates outcome concerns reported in Robinson et al. above.
Epidemiological Data Sources

Agency for Healthcare Research and Quality (AHRQ). HCUP Kids’ Inpatient Database (KID), 2016, 2019, 2022. Healthcare Cost and Utilization Project.
https://www.ahrq.gov/data/hcup/

AHRQ HCUP Fast Stats — NAS State-Level Rates 2018–2023.
https://datatools.ahrq.gov/hcup-fast-stats

Kaiser Family Foundation / T-MSIS Medicaid Analysis — Maternal OUD Estimates.
https://www.kff.org/medicaid/opioid-use-disorder-and-treatment-among-pregnant-and-postpartum-medicaid-enrollees/

Important Notice

This document is intended for healthcare professionals only. It is provided for informational and educational purposes. All clinical decisions should be made by qualified medical personnel in accordance with applicable clinical guidelines, institutional protocols, and individual patient circumstances. ESC study citations should be verified via PubMed (pubmed.ncbi.nlm.nih.gov) for final DOIs and full-text access. Prapela SVS must be used in accordance with its FDA-authorized indication and Instructions for Use. Prapela SVS is compatible with both Finnegan and ESC-based care pathways — clinicians should follow their institutional protocol for NOWS assessment and management.

Request Full Clinical Evidence Package

Request Clinical Information